This proposal constitutes the renewal application of the Pediatric Oncology Clinical Research Training Program (POCRTP), developed by Baylor College of Medicine's Texas Children's Cancer Center. This training program is predicated on the premise that the development of pediatric oncologists and pediatric oncology nurses who are highly trained in clinical research is essential for continued progress to be made in the treatment of childhood cancer. This renewal application highlights the impressive academic accomplishments and progress of the individual Scholars recruited during the last ten years. The program is structured to provide a formal, comprehensive, multidisciplinary clinical research educational program that trains (1) pediatricians who have completed a three-year pediatric hematology-oncology fellowship training program and are board eligible or certified in that subspecialty and, (2) Ph.D. nurses with a career interest in pediatric oncology clinical research. Trainees, in this """"""""one-track"""""""" program, are designated """"""""Paul Calabresi Scholars"""""""". They receive a two to three year comprehensive, didactic mentored training experience in the design, implementation, conduct and analysis of clinical research trials. The program emphasizes training in therapeutic research that occurs in team research settings in which basic and clinical scientists interact to expedite the translation of basic research discoveries into patient-oriented therapeutic cancer research. The program includes participation in a core didactic course in clinical investigation and trial design, provided through Baylor College of Medicine's Clinical Scientist Training Program, and an in-depth clinical research training experience focused in one of five specialized research areas, designated """"""""Pathways"""""""", chosen by the trainee. The POCRTP Pathways include Clinical Pharmacology, Neuro-oncology, Cell and Gene Therapy, Hematologic Malignancy or Solid Tumors. The research experience within each Pathway is tailored to meet the individual Scholar's long-term research goals. All Scholars receive comprehensive mentorship by both a laboratory research and a clinical research mentor and receive in depth instruction in clinical trial design, statistical analysis, research ethics and regulatory requirements and guidelines. In addition, Scholars design and conduct clinical trials in their respective Pathways. An elective rotation at the National Cancer Institute's Cancer Therapy Evaluation Program is a feature of this program. The experience to date indicates that Scholars who complete this program are exceptionally well trained in clinical research, very successful in obtaining NIH funding and well positioned to become future leaders in pediatric oncology clinical research.
This Pediatric Oncology Clinical Research Training Program provides a comprehensive clinical research educational program that trains pediatric oncologists and doctoral-trained pediatric oncology nurses in pediatric oncology clinical research. The program goal is to produce the next generation of leaders in the field of pediatric cancer research. The trainees, designated Paul Calabresi Scholars, receive a mentored training experience in the design, implementation, conduct and analysis of clinical research trials with the ultimate goal of translating basic research discoveries into innovative treatments that will improve the prognosis of children with cancer.
|Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34|
|Rau, Rachel E; Carroll, Andrew J; Heerema, Nyla A et al. (2016) Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. Br J Haematol :|
|DeRenzo, Christopher; Gottschalk, Stephen (2016) Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update. J Clin Cell Immunol 7:|
|Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81|
|Stevens, Alexandra M; Ruiz, Marcos J; Gerbing, Robert B et al. (2015) Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica 100:e496-500|
|Rodgers, Cheryl; Wills-Bagnato, Patricia; Sloane, Richard et al. (2015) Health-Related Quality of Life among Children and Adolescents during Hematopoietic Stem Cell Transplant Recovery. J Pediatr Oncol Nurs 32:329-36|
|Sison, Edward Allan R; Magoon, Daniel; Li, Li et al. (2015) POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget 6:30902-18|
|Simko, Stephen J; McClain, Kenneth L; Allen, Carl E (2015) Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol 169:299-301|
|Heczey, Andras; Louis, Chrystal (2015) IMAGES IN CLINICAL MEDICINE. Osteopetrosis and Erlenmeyer-Flask Deformity. N Engl J Med 373:e12|
|Kilburn, Lindsay B; Kocak, Mehmet; Decker, Rodney L et al. (2015) A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol 17:303-11|
Showing the most recent 10 out of 55 publications